Ullernchausseen 64, 0379 Oslo
Om jobben
Stillingstittel
Postdoc fellowship
Oppstart
31. oktober 2025
Type ansettelse
Engasjement, heltid 100%
Arbeidstid
Dagtid, ukedager
Arbeidsspråk
Engelsk
Antall stillinger
1
Søk senest mandag 8. september
A postdoctoral fellowship in the field of cancer immunotherapy to work on “Safety-Enhanced Chimeric Antigen Receptors (SECAR)” will be available for a period of 30 months starting from November 2025. This postdoctoral fellowship is funded by Helse Sør -Øst.
The Section for Cellular Therapy has around 40 employees, divided between a clinical Unit (GMP facility) and the Translational Research Unit (counting 18 employees), which is developing pre-clinical solutions in cancer immunotherapy. We have produced the first Norwegian CAR molecule - ananti-CD37CAR (Köksal, Dillard et al. 2019, Caulier et al. 2024). Since then, our collection has grown to almost 20 molecules, prepared either from our own antibody stock or from home-made/self-produced antibodies. Our unit has the capacity to perform full pre-clinical validations of TCR and CAR molecules: Radium-1 TCR was also the first synthetic TCR ever tested in an academic clinical trial in Scandinavia (Radium-1 TCR, NCT03431311; Maggadottir et al. 2024). Furthermore, our discoveries have led to the establishment of two biotech spin-offs: Ultimovacs and Zelluna AS, now Zelluna ASA. We are located at the Oslo Cancer Cluster Incubator (https://occincubator.com/), next to the Radium Hospital, which represents an excellent environment for innovative development.
Oslo University Hospital is a workplace with great diversity. We believe this is crucial for solving our tasks in the best possible way. We want this diversity to be reflected among the applicants for our positions, and we encourage all qualified candidates, regardless of background, to apply!
Project description
Chimeric Antigen Receptor (CAR) molecules have shown outstanding therapeutic effects for the treatment of otherwise fatal cancers; however, clinical benefits have so far only been observed in a few tumour types. The present project aims at delivering potent CAR molecules with safer profile for clinical use in cancer.
The focus lies on (but is not restricted to) treatment of AML, B cell malignancies and solid tumours with peritoneal metastases. The current project is based on improvement of molecules that were recently published (Casey et al. 2023, Caulier et al. 2024, Abrantes & Forcados et al. 2025-accepted).However, it also includes the identification, design and testing of new constructs.
Qualifications
The candidates must hold a PhD degree in Biology or Biochemistry. Other corresponding education in science (chemistry, physics, medicine, pharmacy, etc.) will be evaluated.
Knowledge and practical experience in all the following domains are mandatory and should be documented:
- Immune cell culture (PBMC isolation, primary T-cell manipulation and functional assays)
- Immunological methods (flowcytometry, ELISA)
- Animal experiment (FELASA-C or equivalent)
- Molecular biology (cloning, RNA isolation, qPCR, retro- or lentivirus manipulation)
- Cell biology: spheroid, organoid culture or organ on a chip
- Protein expression and purification (bacteria or mammalian cells)
- Immunotherapy: vaccine development, BiTE, immune Receptor work (TCR, CAR, or others)
- Advanced microscopy (confocal) or live cell imaging
The application (in English) must include:
Motivation letter (1 page maximum) containing a short description of why you want to join us, how you will contribute to the team and your previous lab experience including the required above-listed mandatory techniques; Other relevant skills can also be included in addition to these
CV (1 page maximum) which should summarize education and previous positions. It should also include a list of laboratory techniques mastered, prizes, grants, awards and all relevant information about your skills
List of publications (2 pages maximum) with a short description of your contribution (patents as well as papers in preparation or submitted can be included)
Official copies of educational certificates (University levels) with grades
Please respect the document length and do not use AI: exceeding document page number, addition of unrequested documents and AI-generated documents will lead to disqualification.
Kontaktinformasjon
Sebastien Philippe Wälchli, Group leader, +4747347052, [email protected]
Arbeidssted
Ullernchausseen 64
0379 Oslo
Nøkkelinformasjon:
Arbeidsgiver: Oslo universitetssykehus HF
Referansenr.: 5003276864
Stillingsprosent: 100%
Contract
Startdato: 01.11.2025
Søknadsfrist: 08.09.2025
Kontaktperson for stillingen
Sebastien Philippe Wälchli
Group leader
+4747347052
[email protected]
Om bedriften
Oslo University Hospital is a highly specialized hospital in charge of extensive regional and local hospital assignments. As Scandinavia’s largest hospital, we carry out more than 1.2 million patient treatments each year. The hospital has a nationwide responsibility for a number of national and multi-regional assignments, and has several national centers of competence. Oslo University Hospital is responsible for approximately 50 percent of all medical and health care research conducted at Norwegian hospitals, and is a significant role player within the education of a large variety of health care personnel.
Sektor
Offentlig
Nettsted
https://www.oslo-universitetssykehus.no/
Annonsedata
Stillingsnummer
1443e76a-a0af-4402-adf6-ff8700488b7e
Hentet fra
talentech
Referanse
57602204181347d0904da68cd5b323c4
Report job
